The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of lung cancer.
The following sections include:
- Associated ICD-9-CM codes used for the classification of lung cancer
- Drugs that have been FDA-approved for the treatment of lung cancer
- Drugs that are Compendia listed for off-label use for lung cancer based on clinical studies that suggest beneficial use in some cases. Please note: If a check mark appears in the FDA column it will NOT appear in the Compendia off-label use column
- Corresponding HCPCS/CPT® codes and code descriptions
*When billing a nonclassified medication using a CMS 1500 claim form, you must include both the HCPCS code (ie, J8999 for Xalkori) in Column 24D and the drug name, strength, and NDC (National Drug Code) in Box 19 or 24A to ensure appropriate reimbursement.
Please note: Check with payer regarding correct placement of Medication Information in Box 19 or 24A.
References
HCPCS Level II Expert 2013 • Current Procedural Terminology (CPT®) 2013 (copyright 2013 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association) • ICD-9-CM for Professionals Volumes 1, 2, 2013 • FDA-approved indication (from product prescribing information) • Compendia references available upon request • www.ReimbursementCodes.com powered by RJ Health Systems International, LLC, Rocky Hill, Connecticut • CMS (Centers for Medicare and Medicaid Services)
CPT® indicates Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System.
